CN102600372A - Chinese medicinal composition for preventing Parkinsonism - Google Patents
Chinese medicinal composition for preventing Parkinsonism Download PDFInfo
- Publication number
- CN102600372A CN102600372A CN2012100630083A CN201210063008A CN102600372A CN 102600372 A CN102600372 A CN 102600372A CN 2012100630083 A CN2012100630083 A CN 2012100630083A CN 201210063008 A CN201210063008 A CN 201210063008A CN 102600372 A CN102600372 A CN 102600372A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- group
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to application of a Chinese medicinal composition in preparing a medicament for preventing Parkinsonism. The Chinese medicinal composition is prepared from the following bulk pharmaceutical chemicals in parts by weight: 5 to 12 parts of gastrodia elata, 5 to 10 parts of astragalus mongholicus, 5 to 10 parts of prepared rehmannia root, 5 to 15 parts of white peony root, 5 to 10 parts of Chinese angelica, 5 to 10 parts of uncaria, and 2 to 10 parts of stiff silkworm. The invention has the following advantages: the Chinese medicinal composition has the compatibility in accordance with the principle of 'monarch, minister, assistant and guide' of Chinese medicaments and has the advantages of few drugs, high curative effect, no toxic or side effect, low price and the like; principles of a method of tonifying Qi and activating blood, a method of nourishing yin and suppressing excessive yang, a method of calming liver wind, a method of activating blood circulation to remove stasis, a method of dredging collaterals and calming wind are adopted, treatment is started from the pathogen fundamentally, and the Chinese medicament is applied according to symptoms to achieve the prevention effect; the Chinese medical composition is simple in preparation method, low in cost and environmentally-friendly, is suitable for long-term taking, is a safe and effective Chinese medicinal composition for preventing the Parkinsonism and movement complications, and is excellent in application prospect.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, specifically, is the Parkinsonian Chinese medicine composition of a kind of prevention.
Background technology
Parkinson disease (Parkinson ' s disease, PD) be the common nervous system degeneration illness of middle-aged and elderly people, mainly reach the nigrostriatum path dopamine mediator that causes thus and reduce relevant with black substance dense area dopaminergic neuron degeneration disappearance.Through clinical practice for many years, it is generally acknowledged that levodopa is still the most effectively medicine.But symptom fluctuation, the dyskinesia and mental symptom can appear in most of patient after the prolonged application.In addition laboratory find the high concentration dopamine (dopamine, DA) with levodopa because autoxidation produces free radical, can cause the neurocyte degeneration necrosis.Therefore, the associating other drug prevents PD and PD motor complication very urgent jointly.
In addition, discover that the development of striatum GRKs and Arrestins change of Expression and PD is in close relations.In recent years research shows; The generation of parkinson disease motor complication is activated in close relations with the direct path and the signal transduction pathways such as downstream cAMP deopendent protein kinases (PKA), ERK thereof of expressing the D1 receptor; Phosphorylated protein-32 (the dopamine and cAMP-regulated phosphoprotein of Mr 32000 that its downstream signal transducin dopamine and adenosine cyclophosphate are regulated; The change of albumen Thr75 site Expression of phosphorylated DARPP-32) possibly participated in unusual fluctuation disease (1evodopa-induced dyskinesia, morbidity LID).
Think at present and use levodopa controlled release agent, dopamine-receptor stimulant, monoamine oxidase B (monoamine oxidase-B type; MAO-B) inhibitor and catechol-oxygen position-methyltransferase inhibitors (eateehol-O-methyl transferase inhibitor, but the COMTI) appearance of delayed motion complication.But these medicines often side effect are bigger, form drug resistance easily, should not take for a long time.China is accumulating rich experiences aspect the Chinese medicine prevention PD, and summing up its prevention principle is the benefiting QI for activating blood circulation method, the nourishing YIN for attracting YANG method, and the suppressing the hyperactive liver to relieve the wind syndrome method is rubbed the muscle method that relieves dizziness, high fever, infantile convulsions, epilepsy, etc., activating blood and removing stasis Method and collateral dredging rule such as relieve dizziness, high fever, infantile convulsions, epilepsy, etc.
Chinese patent document CN100409867C discloses a kind of capsule that only quivers that relieves dizziness, high fever, infantile convulsions, epilepsy, etc., and the herbal mixture of being made up of the Radix Paeoniae Alba, Ramulus Uncariae Cum Uncis etc. is provided, and prevention PD improves tremble symptom, myotonia, akinesia shape.Li Min etc. have proposed invigorating kidney, promoting blood circulation Chinese medicine can improve PD patient moving complication symptom, and curative effect with the prevention time lengthening increase, this invigorating kidney, promoting blood circulation Chinese medicine is by Fructus Corni 10g; Radix Polygoni Multiflori 15g; Radix Salviae Miltiorrhizae 15g, Chinese medicines such as Hirudo 6g form, but not disclose other Chinese medicine ingredients (see for details: Li Min etc. the invigorating kidney, promoting blood circulation granule prevents the clinical research of parkinson disease motor complication. Chinese Chinese medicine magazine; 2011,26 (6): 1296-1299.).But also do not appear in the newspapers at present about the Parkinsonian Chinese medicine composition of a kind of prevention.
Summary of the invention
The objective of the invention is to deficiency of the prior art, the application of a kind of Chinese medicine composition in the Parkinsonian disease medicament of preparation prevention is provided.
One purpose more of the present invention is to provide a kind of prevention Parkinsonian Chinese medicine composition.
For realizing above-mentioned purpose; The technical scheme that the present invention takes is: the application of a kind of Chinese medicine composition in the Parkinsonian disease medicament of preparation prevention, described Chinese medicine composition is processed by following bulk drugs: Rhizoma Gastrodiae 5-12 part, Radix Astragali 5-10 part, Radix Rehmanniae Preparata 5-10 part, Radix Paeoniae Alba 5-15 part, Radix Angelicae Sinensis 5-10 part, Ramulus Uncariae Cum Uncis 5-10 part, Bombyx Batryticatus 2-10 part.
Described Chinese medicine composition is processed by following bulk drugs: Rhizoma Gastrodiae 6-10 part, Radix Astragali 6-9 part, Radix Rehmanniae Preparata 6-9 part, Radix Paeoniae Alba 8-13 part, Radix Angelicae Sinensis 6-7 part, Ramulus Uncariae Cum Uncis 6-9 part, Bombyx Batryticatus 4-6 part.
Described Chinese medicine composition is processed by following bulk drugs: 8 parts in Rhizoma Gastrodiae, 8 parts of the Radixs Astragali, 8 parts of Radix Rehmanniae Preparata, 10 parts of Radix Paeoniae Alba, 7 parts of Radix Angelicae Sinensis, 8 parts of Ramulus Uncariae Cum Uncis, 6 parts of Bombyx Batryticatus.
The application of described Chinese medicine composition in the disease medicament of preparation prevention parkinson disease motor complication.
For realizing above-mentioned second purpose; The technical scheme that the present invention takes is: the Parkinsonian Chinese medicine composition of a kind of prevention, described Chinese medicine composition is processed by following bulk drugs: Rhizoma Gastrodiae 5-12 part, Radix Astragali 5-10 part, Radix Rehmanniae Preparata 5-10 part, Radix Paeoniae Alba 5-15 part, Radix Angelicae Sinensis 5-10 part, Ramulus Uncariae Cum Uncis 5-10 part, Bombyx Batryticatus 2-10 part.
Described Chinese medicine composition is processed by following bulk drugs: Rhizoma Gastrodiae 6-10 part, Radix Astragali 6-9 part, Radix Rehmanniae Preparata 6-9 part, Radix Paeoniae Alba 8-13 part, Radix Angelicae Sinensis 6-7 part, Ramulus Uncariae Cum Uncis 6-9 part, Bombyx Batryticatus 4-6 part.
Described Chinese medicine composition is processed by following bulk drugs: 8 parts in Rhizoma Gastrodiae, 8 parts of the Radixs Astragali, 8 parts of Radix Rehmanniae Preparata, 10 parts of Radix Paeoniae Alba, 7 parts of Radix Angelicae Sinensis, 8 parts of Ramulus Uncariae Cum Uncis, 6 parts of Bombyx Batryticatus.
The application of described Chinese medicine composition in the disease medicament of preparation prevention parkinson disease motor complication.
The dosage form of described Chinese medicine composition is tablet, capsule, granule, mixture, oral liquid or syrup.
The invention has the advantages that:
1, Chinese medicine composition of the present invention, its compatibility meet Chinese medicine " monarch " principle, and the flavour of a drug number is less; Advantages such as having the curative effect height, have no side effect, price is low adopts the benefiting QI for activating blood circulation method, the nourishing YIN for attracting YANG method; The suppressing the hyperactive liver to relieve the wind syndrome method is rubbed the muscle method that relieves dizziness, high fever, infantile convulsions, epilepsy, etc., activating blood and removing stasis Method and collateral dredging rule such as relieve dizziness, high fever, infantile convulsions, epilepsy, etc.; Start with from cause of disease at all, suit the remedy to the case, to reach preventive effect;
2, method for preparing is simple, and cost is low, and is environmentally friendly, is suitable for taking for a long time, is a kind of Chinese medicine composition that prevents parkinson disease and parkinson disease motor complication safely and effectively, has a good application prospect.
Description of drawings
Accompanying drawing 2 is the influences to PD rat model agent peak number of revolutions of various dose Chinese medicine composition, and # Western medicine group and small dose group compare, all P < 0.05; * middle dose groups and small dose group compare, all P < 0.01; + heavy dose of group compares with middle dose groups, all P < 0.05.
Accompanying drawing 4 is Chinese medicine composition various dose Western results to the influence of PD rat model striatum district GRK6, and 1,2 is sham operated rats, and 3,4 is the PD matched group; 5,6 is Western medicine group; 7,8 is the TCM-small dose group, and 9,10 is dose groups among the TCM-, and 11,12 is the heavy dose of group of TCM-; 1,3,5,7,9,11 for not damaging side, and 2,4,6,8,10,12 are the damage side; * compare with sham operated rats, p < 0.01; # and PD matched group compare, and p < 0.05; + TCM and Western medicine group compare, and p < 0.01.
Accompanying drawing 5 is Chinese medicine various dose SABC results to the influence of PD motor complication rat model striatum district β-arrestin1, and 1 is sham operated rats, and 2 is the PD matched group; 3 is Western medicine group; 4 is the TCM-small dose group, and 5 is dose groups among the TCM-, and 6 is the heavy dose of group of TCM-; U is not for damaging side, and L is the damage side.
Accompanying drawing 6 is Chinese medicine various dose Western results to the influence of PD motor complication rat model striatum district β-arrestin1; 1,2 is sham operated rats; 3,4 is the PD matched group, and 5,6 is Western medicine group, and 7,8 is the TCM-small dose group; 9,10 is dose groups among the TCM-, and 11,12 is the heavy dose of group of TCM-; 1,3,5,7,9,11 for not damaging side, and 2,4,6,8,10,12 are the damage side.
Accompanying drawing 7 is Chinese medicine various dose SABC results to the influence of PD motor complication rat model striatum district phosphorylation DARPP-32 (Thr75) expression, the A sham operated rats, and B is the PD matched group; C is a Western medicine group; D is the TCM-small dose group, and E is a dose groups among the TCM-, and F is the heavy dose of group of TCM-.
Accompanying drawing 8 is Chinese medicine various dose Western results to the influence of PD motor complication rat model striatum district phosphorylation DARPP-32 (Thr75) expression; 1 is sham operated rats; 2 is the LID matched group, and 3 is Western medicine group, and 4 is the TCM-small dose group; 5 is dose groups among the TCM-, and 6 is the heavy dose of group of TCM-.
Accompanying drawing 9 is Chinese medicine various dose SABC results to the influence of PD motor complication rat model striatum district phosphorylation ERK1/2 expression, the A sham operated rats, and B is the PD matched group; C is a Western medicine group; D is the TCM-small dose group, and E is a dose groups among the TCM-, and F is the heavy dose of group of TCM-.
Accompanying drawing 10 is Chinese medicine various dose Western results to the influence of PD motor complication rat model striatum district phosphorylation ERK1/2 expression, and 1 is sham operated rats, and 2 is the PD matched group, and 3 is the TCM-small dose group, and 4 is dose groups among the TCM-, and 5 is the heavy dose of group of TCM-.
The specific embodiment
Below in conjunction with accompanying drawing the specific embodiment provided by the invention is elaborated.
The present invention provides a kind of prevention Parkinsonian Chinese medicine composition, and described Chinese medicine composition is processed by following bulk drugs: Rhizoma Gastrodiae 5-12 part, Radix Astragali 5-10 part, Radix Rehmanniae Preparata 5-10 part, Radix Paeoniae Alba 5-15 part, Radix Angelicae Sinensis 5-10 part, Ramulus Uncariae Cum Uncis 5-10 part, Bombyx Batryticatus 2-10 part.
The preparation (one) of embodiment 1 Chinese medicine composition
5 parts in Rhizoma Gastrodiae, 10 parts of the Radixs Astragali, 5 parts of Radix Rehmanniae Preparata, 15 parts of Radix Paeoniae Alba, 5 parts of Radix Angelicae Sinensis, 10 parts of Ramulus Uncariae Cum Uncis, 2 parts of Bombyx Batryticatus, conventional method decocts.
The preparation (two) of embodiment 2 Chinese medicine compositions
6 parts in Rhizoma Gastrodiae, 9 parts of the Radixs Astragali, 6 parts of Radix Rehmanniae Preparata, 14 parts of Radix Paeoniae Alba, 6 parts of Radix Angelicae Sinensis, 9 parts of Ramulus Uncariae Cum Uncis, 3 parts of Bombyx Batryticatus, conventional method decocts.
The preparation (three) of embodiment 3 Chinese medicine compositions
7 parts in Rhizoma Gastrodiae, 7 parts of the Radixs Astragali, 7 parts of Radix Rehmanniae Preparata, 12 parts of Radix Paeoniae Alba, 8 parts of Radix Angelicae Sinensis, 7 parts of Ramulus Uncariae Cum Uncis, 4 parts of Bombyx Batryticatus, conventional method decocts.
The preparation (four) of embodiment 4 Chinese medicine compositions
8 parts in Rhizoma Gastrodiae, 8 parts of the Radixs Astragali, 8 parts of Radix Rehmanniae Preparata, 10 parts of Radix Paeoniae Alba, 7 parts of Radix Angelicae Sinensis, 8 parts of Ramulus Uncariae Cum Uncis, 6 parts of Bombyx Batryticatus, conventional method decocts.
The preparation (five) of embodiment 5 Chinese medicine compositions
9 parts in Rhizoma Gastrodiae, 6 parts of the Radixs Astragali, 9 parts of Radix Rehmanniae Preparata, 9 parts of Radix Paeoniae Alba, 9 parts of Radix Angelicae Sinensis, 6 parts of Ramulus Uncariae Cum Uncis, 5 parts of Bombyx Batryticatus, conventional method decocts.
The preparation (six) of embodiment 6 Chinese medicine compositions
10 parts in Rhizoma Gastrodiae, 5 parts of the Radixs Astragali, 10 parts of Radix Rehmanniae Preparata, 8 parts of Radix Paeoniae Alba, 10 parts of Radix Angelicae Sinensis, 5 parts of Ramulus Uncariae Cum Uncis, 7 parts of Bombyx Batryticatus, conventional method decocts.
The preparation (seven) of embodiment 7 Chinese medicine compositions
11 parts in Rhizoma Gastrodiae, 10 parts of the Radixs Astragali, 8 parts of Radix Rehmanniae Preparata, 7 parts of Radix Paeoniae Alba, 8 parts of Radix Angelicae Sinensis, 10 parts of Ramulus Uncariae Cum Uncis, 8 parts of Bombyx Batryticatus, conventional method decocts.
The preparation (eight) of embodiment 8 Chinese medicine compositions
12 parts in Rhizoma Gastrodiae, 8 parts of the Radixs Astragali, 6 parts of Radix Rehmanniae Preparata, 5 parts of Radix Paeoniae Alba, 6 parts of Radix Angelicae Sinensis, 8 parts of Ramulus Uncariae Cum Uncis, 10 parts of Bombyx Batryticatus, conventional method decocts.
Need to prove that it is the conventional manufacture method of Chinese medicine decoction that the described conventional method of embodiment 1-8 decocts, and is about to described crude drug decocte with water and becomes decoction.
The preparation of embodiment 9 Chinese medicine composition tablets/capsules agent
Get the arbitrary described Chinese medicine composition of embodiment 1-8, add 6-10 times of water gaging, decocted 1-3 hour, leach medicine juice.Add 6-10 times of water gaging again, decocted 0.5-2 hour, leach medicine juice, merge the secondary decocting liquid, leave standstill, the leaching supernatant concentrates, and puts coldly, adds concentrated solution 2-3 and doubly measures ethanol, stirs deposition and spends the night.Get supernatant, be concentrated into thick extractum, or be concentrated into thick extract dry and be prepared into granule; Add pharmaceutical aids, vacuum drying is pulverized and is granulated, and is pressed into tablet or fills encapsulated.
The preparation of embodiment 10 Chinese medicinal composition granules
Get the arbitrary described Chinese medicine composition of embodiment 1-8, add 6-10 times of water gaging, decocted 1-3 hour, leach medicine juice.Add 6-10 times of water gaging again, decocted 0.5-2 hour, leach medicine juice, merge the secondary decocting liquid, leave standstill, the leaching supernatant concentrates, and puts coldly, adds concentrated solution 2-3 and doubly measures ethanol, stirs deposition and spends the night.Get supernatant, be concentrated into thick extractum, or be concentrated into thick extract dry and be prepared into granule; Add suitable pharmaceutical aids, granulate, drying, granulate gets granule, packing.
The preparation of embodiment 11 Chinese medicine composition mixture/oral liquid/syrups
Get the arbitrary described Chinese medicine composition of embodiment 1-8, add 6-10 times of water gaging, decocted 1-3 hour, leach medicine juice.Add 6-10 times of water gaging again, decocted 0.5-2 hour, leach medicine juice, merge the secondary decocting liquid, leave standstill, the leaching supernatant concentrates, and puts coldly, adds concentrated solution 2-3 and doubly measures ethanol, stirs deposition and spends the night.Get supernatant, be concentrated into thick extractum, or be concentrated into thick extract dry and be prepared into granule; Add suitable pharmaceutical aids, process mixture, oral liquid or syrup.
The preclinical test of embodiment 12 Chinese medicine compositions of the present invention
One, experimental technique
1.PD rat model preparation:Prepare the PD rat model according to methods such as Ba Maowen.Get 65 rats and get into experiment, wherein 5 is sham operated rats, in MES (MFB) injecting normal saline.Lumbar injection 3% pentobarbital sodium anesthetized rat; Strict tack cranium position fixedly rat is shown the rat brain stereotaxic atlas in stereo brain orienting instrument with reference to the bag new people, confirms right side medial forebrain bundle (right medical forebrain; MFB) coordinate: 1. 3.7 mm behind the bregma; Sagittal suture right side 1.7 mm, 7.8 mm under the cranial periosteum, front tooth line 2.4 mm; 2. 4.4 mm behind the bregma, sagittal suture right side 1.2 mm, 7.8 mm under the cranial periosteum, front tooth line 2.4 mm.By the boring of above-mentioned definite injection site, extract 6-OHDA6 μ l (containing 0.2% ascorbic normal saline configuration, concentration 4 μ g/ μ l) with the microsyringe of 10 μ l, the withdraw of the needle behind every some injection 3 μ l, let the acupuncture needle remain at a certain point 10 min, stitching wound surface.After 3 weeks, rats by intraperitoneal injection apomorphine (0.5 mg/kg), average speed>7 times/min is successful PD model.
The model preparation is measured with behavioristics:The PD model of 25 successes is divided into 3 groups greatly at random.(1) PD matched group: PD rat model lumbar injection 0.2% vitamin C liquid 29 days; (2) Western medicine processed group: lumbar injection LDME+benserazide (50 mg/kg LDMEs and 25 mg/ kg benserazides, be dissolved in contain in the 0.2% ascorbic sterilization normal saline), continues 29d at 9 at 2 times/d at (in the morning with point in afternoons 5); (3) dose groups in Chinese medicine composition small dose group (TCM-small dose group), the Chinese medicine composition (the heavy dose of group of TCM-), the heavy dose of group of Chinese medicine composition (the heavy dose of group of TCM-): give to add respectively on the basis of LDME/benserazide and use Chinese medicine composition of the present invention; 9 ml/kg; 1 filling every day stomach, continuous 4 weeks.Dose groups prepares Chinese medicine composition with reference to embodiment 4 described methods in the Chinese medicine composition; The heavy dose of group of Chinese medicine composition respectively increases by 20% according to each raw material of Chinese medicine medicine of middle dose groups; The Chinese medicine composition small dose group respectively reduces 20% according to each raw material of Chinese medicine medicine of middle dose groups.In therapeutic process, after medication in the morning in the 2nd, 8,15,22,29 day, carry out rat behavior and learn observation and scoring.AIM evaluation: AIM is divided into 4 components (upper limb AIM, the AIM of actinal surface portion, axle property AIM and rotation AIM) to be evaluated, and every part has or not with the order of severity according to it again and is divided into 5 grades (0-4): 0 does not have; 1 persistent period is less than 30s; 2 persistent period are greater than 30s, less than 60s; 3 persistent period, environmental stimuli can make it to stop greater than 60s; 4 persistent period, environmental stimuli can not make it to stop greater than 60s.Every 20min assessment is once observed 1min at every turn after the medication.The AIM total points is added up by the meansigma methods of total mark in observing time, and each component AIM maximum scores is 4 minutes behind 1 rat a drug in theory, and total AIM scoring is 16 minutes.Agent peak number of revolutions: behind the injection levodopa, every 5min record number of revolutions, maximum numbers of revolutions is an agent peak number of revolutions.
SABC shows the variation of striatum β-arrestin1, GRK6, DARPP-32 (Thr75) and ERK1/2:Finish injection back 12h, the anesthesia of 3% pentobarbital sodium, left ventricle is poured into 4% paraformaldehyde and is fixed, and broken end is got behind the brain in the same fixed liquid fixedly 8h of back, and piece, gradient alcohol dehydration, xylene are transparent through repairing, use FFPE behind the waxdip.The row paraffin section, slice thickness is 5 μ m.Paraffin section de-waxing is to water; 3% hydrogen peroxide room temperature lucifuge is hatched 5min, to eliminate the endogenous catalase activity; 1nmol/l ethylenediaminetetraacetic acid-Tris-hydrogen chloride of PH7.7 (repair by the EDTA-Tris-HCl microwave heating; 1% bovine serum albumin room temperature envelope 20min; Incubated overnight in the anti-Mus GRK6 of rabbit antibody, the anti-Mus β of rabbit-arrestin1 polyclonal antibody, the anti-Mus DARPP-32 of rabbit antibody, anti-phosphorylation DARPP-32 (Thr75) antibody, the total ERKl/2 of rabbit Chinese People's Anti-Japanese Military and Political College Mus and 4 ℃ of wet boxes of the Mus phosphorylation ERKl/2 of rabbit Chinese People's Anti-Japanese Military and Political College monoclonal antibody; The biotin labeling two that drips dilution is anti-, hatches 20min for 37 ℃; Drip the horseradish peroxidase-labeled strepto-avidin of dilution, hatch 20min for 37 ℃; Benzidine (3,3 ˊ-diaminobenzidine tetrahydrochloride, DAB) chromogenic reagent, tap water flushing, dehydration, transparent, mounting afterwards.All use the abundant rinsing of 0.01mol/l TBS between each step, TBS replaces one to resist as negative control.Examine under a microscope the SABC section; Each is observed the district and gets 5 not overlapping visuals field at random; Observe down in high power lens (10 * 40); Adopt OLYMPUS-IX50 to become phase system to take, Image-Pro Plus 5.1 imgae processing softwares carry out semi-quantitative analysis, calculate positive cell index (IOD)=positive cell area * correction OD value (measurement zone optical density-background indensity).
Method detects the expression of β-arrestin1, GRK6, DARPP-32 (Thr75) and ERK1/2:Last injection back 3h, the anesthesia of 3% pentobarbital sodium, broken end is got brain rapidly, peels off the bilateral striatum on ice, and ultrasonic degradation extracts total protein.After measuring protein concentration, put-80 ℃ frozen subsequent use.40 μ g egg door samples separate through 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), change the film appearance with electricity and are transferred on polyvinylidene fluoride (PVDF) film.Confining liquid (5% defatted milk powder) room temperature sealing 2h; Dilute anti-GRK6 antibody (1: 500), anti-β-arrestin1 antibody (1:500), anti-total DARPP-32 antibody (1:1000) or anti-phosphorylation DARPP-32 (Thr75) antibody (1:1000), anti-total ERKl/2 antibody (1:1000) or anti-phosphorylation ERKl/2 antibody (1:500) or anti-β-actin (l:1000), 4 ℃ of jog incubated overnight according to respective concentration.Add two next day and resist, shaking table is hatched 1 h under the room temperature; Drip ECL colour developing mixed liquor, the exposure of Bio-Rad gel imaging appearance, video picture.Western blot image adopts the SmartView2000 image analysis software to calculate the product of each sample destination protein band OD value and area value, thereby it is quantitative to carry out protein band density.
Statistical analysis technique
Experimental data adopts SPSS 13.0 statistical softwares to analyze.The gained measurement data is with (
± s) expression of mean ± standard deviation; The relatively employing one factor analysis of variance of a plurality of sample averages relatively adopts the t check in twos.< 0.05 is that difference has statistical significance with P.
Two, result
1. Chinese medicine composition is to the influence of PD rat model behavior
1.1 Chinese medicine composition is to the influence of each component AIM scoring of PD rat model
With regard to the AIM of actinal surface portion scoring, average does not have significant difference between the 2nd day each group.8th, 15,22,29 days each the group between the average significant difference (
F=4.98,
F=22.70,
F=30.96,
F=23.27,
P<0.01).Wherein small dose group reduces than the Western medicine processed group the AIM of actinal surface portion scoring in the 22nd day, and difference has statistical significance (t=2.50, P<0.05), all the other several days equal not statistically significants of difference; In the 8th, 15,22,29 days AIM of actinal surface portion of dose groups scoring smaller dose group obviously reduce, difference have statistical significance (t=2.86, t=3.80, t=4.38, t=6.54, all
P<0.05); In dose groups and heavy dose of group relatively, the only middle dose groups actinal surface AIM of the portion scoring of big dose groups reduction in the 22nd day, difference have statistical significance (
t=2.50,
P<0.05).
With regard to upper limb AIM scoring, the 2nd, 8 day each class mean no significant difference, between the 15th, 22,29 day each group average difference have statistical significance (
F=15.12,
F=32.86,
F=35.80,
P<0.01).Medication the 2nd day and small dose group upper limb AIM scoring in the 8th day and Western medicine processed group be there was no significant difference relatively, is lower than Western medicine group to medication small dose group upper limb AIM scoring in the 15th, 22,29 days, difference have statistical significance (
t=4.45,
t=4.47, all
P<0.01).15th, dose groups obviously reduces than small dose group upper limb AIM scoring in 22,29 days, difference have statistical significance (
t=3.40,
t=4.04,
t=3.95, all
P<0.01).Compare the difference no difference of science of statistics between heavy dose of group and the middle dose groups.
With regard to axial AIM scoring, between the 15th, 22,29 day each group average difference have statistical significance (
F=3.30,
F=25.06,
F=36.41,
P<0.01).22,29 days axial AIM values of small dose group medication to the reduce than Western medicine processed group, difference have statistical significance (
t=3.93,
t=3.04, all
P<0.05); In dose groups than small dose group relatively, only in the 29th day difference have statistical significance (
t=3.05,
P<0.05); Heavy dose of group has obviously reduced axial AIM value, but compares with middle dose groups, only variant in the 29th day (
t=2.83,
P<0.05), put the difference no difference of science of statistics At All Other Times.
With regard to rotation AIM scoring, average significant difference between the 8th, 15,22,29 day each group (
F=10.50,
F=11.62,
F=18.92,
F=61.26,
P<0.01).The difference not statistically significant is compared in small dose group and Western medicine processed group rotation AIM scoring.In dose groups medication to the 15,22,29 days, rotation AIM scoring is than the obvious reduction of Western medicine group, difference have statistical significance (
t=3.43,
t=5.11,
t=7.63, all
P<0.01); Heavy dose of group and middle dose groups relatively, the 8th, 15,29 day obvious difference (
t=3.81,
t=2.52,
t=3.58, all
P<0.05).
The comparison of table 1 Chinese drug-treated group and Western medicine group AIM scoring (
± S divides)
| Time | Group | Mus number (only) | Actinal surface portion | Upper | Axially | Rotation | |
| 2d | The heavy dose of group of TCM- | 5 | 1.42±0.24 | 1.62±0.26 | 2.38±0.15 | 2.62±0.23 | |
| ? | Dose groups among the TCM- | 5 | 1.40±0.19 | 1.56±0.28 | 2.51±0.22 | 2.71±0.34 | |
| ? | The TCM- |
5 | 1.51±0.17 | 1.58±0.19 | 2.42±0.16 | 2.62±0.23 | |
| ? | The Western medicine processed |
5 | 1.44±0.18 | 1.51±0.22 | 2.49±0.17 | 2.67±0.28 | |
| 8d | The heavy dose of group of TCM- | 5 | 1.51±0.22 | 1.67±0.22 | 2.42±0.24 | 2.60±0.06 | |
| ? | Dose groups among the TCM- | 5 | 1.56±0.18 | 1.76±0.16 | 2.58±0.29 | 2.93±0.19 | |
| ? | The TCM- |
5 | 1.89±0.21 | 1.91±0.19 | 2.76±0.41 | 3.16±0.20 | |
| ? | The Western medicine processed |
5 | 1.82±0.17 | 1.93±0.20 | 2.71±0.41 | 3.20±0.25 | |
| 15d | The heavy dose of group of TCM- | 5 | 1.33±0.11 | 1.51±0.22 | 2.38±0.20 | 2.58±0.15 | |
| ? | Dose groups among the TCM- | 5 | 1.47±0.14 | 1.71±0.22 | 2.69±0.24 | 2.84±0.19 | |
| ? | The TCM- |
5 | 1.84±0.17 | 2.09±0.12 | 2.71±0.37 | 3.09±0.24 | |
| ? | The Western medicine processed |
5 | 2.11±0.22 | 2.18±0.15 | 2.93±0.28 | 3.36±0.28 | |
| 22d | The heavy dose of group of TCM- | 5 | 1.29±0.13 | 1.49±0.23 | 2.24±0.18 | 2.53±0.15 | |
| ? | Dose groups among the TCM- | 5 | 1.49±0.13 | 1.69±0.20 | 2.29±0.13 | 2.67±0.11 | |
| ? | The TCM- |
5 | 1.96±0.20 | 2.13±0.14 | 2.62±0.28 | 3.11±0.21 | |
| ? | The Western medicine processed |
5 | 2.40±0.37 | 2.56±0.16 | 3.18±0.15 | 3.38±0.29 | |
| 29d | The heavy dose of group of TCM- | 5 | 1.20±0.09 | 1.53±0.21 | 2.11±0.78 | 2.29±0.10 | |
| ? | Dose groups among the TCM- | 5 | 1.33±0.21 | 1.67±0.18 | 2.33±0.16 | 2.56±0.14 | |
| ? | The TCM- |
5 | 2.04±0.13 | 2.13±0.20 | 2.76±0.26 | 3.24±0.14 | |
| ? | The Western medicine processed |
5 | 2.36±0.36 | 2.60±0.13 | 3.16±0.13 | 3.47±0.23 |
1.2 various dose group Chinese medicine is to the influence of PD rat model AIM total points
Medication was marked in the 8th, 15,22,29 days; Find low dose group medication to the 15,22,29 days; The AIM total points is that (9.73 ± 0.52), (9.82 ± 0.37) and (10.18 ± 0.32) are divided, than Western medicine group (10.58 ± 0.40), (11.51 ± 0.17) divide and (11.58 ± 0.24) divide obviously and reduce (
t=2.88,
t=9.25,
t=7.77, all
p<0.05).And middle dose groups AIM total points is respectively (8.82 ± 0.36), (8.71 ± 0.47), (8.13 ± 0.37) and (7.89 ± 0.57) and divides and all be lower than the small dose group total points, difference have statistical significance (
t=3.32,
t=3.19,
t=7.56,
t=7.85, all
p<0.05); In the 8th, 15,22 day, heavy dose of group AIM total points was respectively (8.20 ± 0.27), (7.80 ± 0.34), (7.55 ± 0.38) are divided, and middle dose groups is low, difference have statistical significance (
t=3.12,
t=3.44,
t=2.57, all
p<0.05), and the 29th day big dose groups (6.71 ± 1.13) branch compares with middle dose groups, difference not statistically significant (see figure 1).
The various dose Chinese medicine composition is to the influence of PD rat model agent peak number of revolutions
Carried out agent peak number of revolutions in the 8th, 15,22,29 day and detect, find that low dose group scoring (123.6 ± 11.91), (132 ± 10.07), (151 ± 15.73) and (155.8 ± 7.40) are inferior, little with the Western medicine group difference; And middle dose groups and small dose group are relatively, and middle dose groups agent peak number of revolutions is respectively (87.4 ± 15.60), (83.0 ± 21.76), (88 ± 10.20) and (73 ± 15.18), all is lower than small dose group, difference have statistical significance (
t=4.13,
t=4.57,
t=7.51,
t=10.96, all
p<0.05); Heavy dose of group and middle dose groups relatively, the inferior middle dose groups of big dose groups agent peak number of revolutions (51.2 ± 6.76) and (53.8 ± 7.79) was low in the 22nd, 29 day, difference have statistical significance (
t=6.73,
t=2.52, all
p<0.05) (see figure 2).
The various dose Chinese medicine composition is to the influence of PD motor complication rat striatum district signal protein
2.1 the Chinese medicine composition various dose is to the influence of PD rat model striatum district GRK6
Showed by immune group result GRK6 expresses on cell membrane.Each group is not damaged the side average relatively, the difference not statistically significant (
F=0.17,
P>0.05), and each group damage side average significant difference (
F=4.48,
P<0.05).PD injury in rats side GRK6 expression is (4.53 ± 0.85) * 10
3, (6.10 ± 0.55) * 10 of normal rat
3Obviously reduce (
t=9.99,
P<0.01); GRK6 expresses and further is reduced to (3.52 ± 0.71) * 10 after the life-time service levodopa treatment
3, with the PD rat relatively, difference have statistical significance (
t=2.99,
P<0.05); And adding rat with Chinese herb on the prevention, striatal damage side GRK6 expresses and the PD rat is compared, and does not all have further to reduce, and compares small dose group (4.17 ± 1.20) * 10 with the rat of using levodopa
3With the Western medicine group zero difference, the expression of middle dose groups, heavy dose of group damage side GRK6 is respectively (4.21 ± 0.95) * 10
3, (4.78 ± 1.24) * 10
3, with Western medicine group relatively, the GRK6 expression obviously more (
t=3.79,
t=4.84, all
P<0.05) (see figure 3).
Western result and SABC basically identical.With regard to every rat, testing result is with damage side/do not damage the ratio value representation of side, and β-actin is as confidential reference items.Compare with (100.78 ± 5.57) % of sham operated rats, PD rat GRK6 expression is reduced to (81.32 ± 5.94) %, significant difference (
t=7.37,
P<0.01); The levodopa long-term treatment has further reduced the GRK6 expression to (72.66 ± 3.43) %, difference have statistical significance (
t=3.11,
P<0.05); Compare the difference not statistically significant and add with the rat striatum GRK6 expression and the PD rat of Chinese herb on the prevention.With the rat of life-time service levodopa relatively, % is obviously higher for middle dose groups striatum GRK6 expression (83.78 ± 4.50), difference have statistical significance (
t=7.26,
P<0.01), small dose group (79.02 ± 3.15) % and heavy dose of group (80.46 ± 4.74) % and its compare, the remarkable (see figure 4) of difference.
The Chinese medicine various dose is to the influence of PD motor complication rat model striatum district β-arrestin1
SABC shows that β-arrestin1 is expressed in cell membrane, each group damage side average significant difference (F=5.76, P 0.05).The proteic positive cell index of PD rat β-arrestin1 is (3.20 ± 0.75) * 10
4Be lower than (4.50 ± 0.63) * 10 of sham operated rats rat
4, but the difference not statistically significant.After the levodopa long-term treatment, β-arrestin1 expresses further and reduces, and the positive cell index is (2.50 ± 0.49) * 10
4, comparing with the PD rat, difference has statistical significance (t=3.90, P<0.05).Further decline does not appear in the rat β-arrestin1 positive cell index that adds with Chinese medicine, and particularly middle dose groups rat β-arrestin1 positive cell index is (3.67 ± 0.51) * 10
4, increase (t=6.80, P than PD rat<0.01).Large and small dose groups β-arrestin1 positive cell index is respectively (3.20 ± 0.68) * 10
4(3.10 ± 0.59) * 10
4Between relatively, with the PD group relatively, no significant difference (see figure 5).
Western result and SABC basically identical.Every rat Western result is with damage side/do not damage the ratio value representation of side, and β-actin is as confidential reference items.PD rat β-arrestin1 expressing quantity is (76.41 ± 5.12) %, than sham operated rats rat (100.86 ± 6.79) % obviously reduce (
t=11.48,
P<0.01).The levodopa long-term treatment has further reduced β-arrestin1 expression, is (65.04 ± 6.68) %, with PD group rat relatively, difference have statistical significance (
t=8.31,
P<0.01).Add with behind the Chinese herb on the prevention, small dose group β-arrestin1 expression is (69.34 ± 3.36) %, than PD rat group reduce (
t=3.42,
P<0.05), demonstrate the trend similar with Western medicine group; And middle dose groups is respectively (73.42 ± 3.82) % with heavy dose of group and further decline does not appear in (72.36 ± 6.66) %.Simultaneously, middle dose groups and the rat of heavy dose of group striatum β-arrestin1 expression, difference apparently higher than the life-time service levodopa have statistical significance (
t=3.11,
t=3.70,
P<0.05).Compare difference not statistically significant (see figure 6) between middle dose groups and the heavy dose of group.
The influence that the Chinese medicine various dose is expressed PD motor complication rat model striatum district phosphorylation DARPP-32 (Thr75)
Each group damage side average significant difference of SABC demonstration (
F=472.10,
P<0.01).Sham operated rats rat phosphorylation DARPP-32 (Thr75) expression is (7.01 ± 0.57) * 10
6, the PD group is increased to (11.50 ± 0.16) * 10
6, difference have statistical significance (
t=14.07,
P<0.01).After the levodopa long-term treatment, phosphorylation DARPP-32 (Thr75) is expressed as (3.85 ± 0.30) * 10
6, obviously reduce than PD group, difference have statistical significance (
t=38.99,
P<0.01).Add the rat with Chinese medicine, large, medium and small dose groups phosphorylation DARPP-32 (Thr75) expresses and is respectively (12.34 ± 0.19) * 10
6, (11.89 ± 0.47) * 10
6(7.20 ± 0.27) * 10
6, middle dose groups does not all occur significantly reducing with heavy dose of group, and only small dose group reduces.Compare difference not statistically significant (see figure 7) between heavy dose of group and the middle dose groups.
Western result and SABC basically identical, the gray value that sham operated rats rat phosphorylation DARPP-32 (THr75) expresses is (2.06 ± 0.24) * 10
6, PD group rat is (3.04 ± 0.20) * 10
6, two groups of comparing differences have statistical significance (
t=28.95,
P<0.01).Add with not playing preventive effect behind the low dose of Chinese medicine, phosphorylation DARPP-32 (THr75) expression is (1.85 ± 0.15) * 10
6, than the PD rat reduce (
t=19.77,
P<0.01); Rat striatum phosphorylation DARPP-32 (THr75) expression that adds dosage Chinese herb on the prevention in the usefulness is (3.10 ± 0.15) * 10
6, compare with the PD rat, the difference not statistically significant (
P>0.05).Heavy dose of group phosphorylation DARPP-32 (THr75) expression is (3.73 ± 0.17) * 10
6,, than the PD rat have slightly and increase (t=38.57,
P<0.01), simultaneously, dose groups increasing expression in heavy dose of group ratio (
t=21.78,
P<0.01) (see figure 8).
The influence that the Chinese medicine various dose is expressed PD motor complication rat model striatum district phosphorylation ERK1/2
Each group damage side average significant difference of SABC demonstration (
F=117.49,
P<0.01).PD rat phosphorylation ERK12 expression is (4.30 ± 0.23) * 10
4, be lower than (5.20 ± 0.34) * 10 of sham operated rats rat
4, difference have statistical significance (
t=15.32,
P<0.01).After the levodopa long-term treatment, phosphorylation ERK12 expresses and is increased to (8.08 ± 0.37) * 10
4, with PD group relatively, difference have statistical significance (
t=34.13,
P<0.01).Add the rat with Chinese medicine, small dose group phosphorylation ERK12 is expressed as (6.59 ± 0.36) * 10
4, in rising trend, middle dose groups is (4.49 ± 0.34) * 10 with heavy dose of group expression
4(4.26 ± 0.25) * 10
4, all do not occur significantly rising.Relatively, difference is not obvious between heavy dose of group and the middle dose groups.(see figure 9).
Western result and SABC basically identical, the gray value that PD rat phosphorylation ERK1/2 expresses is (2.83 ± 0.17) * 10
6, than (3.50 ± 0.12) * 10 of sham operated rats rat
6Reduce (
t=20.77,
P<0.01); Add the gray value of expressing and be respectively (3.23 ± 0.19) * 10 with the rat striatum phosphorylation ERK12 of large, medium and small dosage Chinese herb on the prevention
6, (3.15 ± 0.16) * 10
6(4.40 ± 0.16) * 10
6, with the PD rat rising is in various degree arranged more all, difference all have statistical significance (
t=13.81,
t=3.41,
t=45.12,
P<0.01).Wherein, middle dose groups phosphorylation ERK12 expression rising amplitude is minimum, the maximum (see figure 10) of small dose group rising amplitude.
Use levodopa and correct the shortage of DA neurotransmitter in PD patient's brain, obviously improve PD patient's motor symptoms, this is the major progress on the PD treatment history.Yet, after levodopa is used 3-5, about 5% PD patient can produce gradually the symptom fluctuation with (or) levodopa " long-term syndrome " such as the dyskinesia.For solving the defective of levodopa treatment; Further study pathogenesis and the corresponding treatment strategy of PD; In recent years; The many scholars of China use Chinese medicine or combination of Chinese and Western medicine method treatment primary disease, improving clinical symptoms, alleviate adverse effect, stop PD, improving aspect such as patient quality of life and obtained better effects, and more and more receiving people's attention.
The traditional Chinese medical science thinks that PD belongs to " tremor syndrome ", and pilosity is born in person in middle and old age's " menses " when exhausting, and " menses " exhausts that to characterize kidney essense deficient, and Rong Wei is two empty, on not nourishing the liver wood, Ru Jinmai not outward, water files to nourish wood, and then hyperactivity of yang due to yin deficiency, palpitaition, sweating, hectic fever, agitation take place frequently; The muscle arteries and veins loses deadlock in gentle existing morning, spasm of limbs, trembles, tetanic, pain, bradykinesia.Take a broad view of the experience of ancient Chinese medicine doctor, take up modern medicine study, observe through facing card, we think, control with QI invigorating reduce phlegm, easing the affected liver relieves dizziness, high fever, infantile convulsions, epilepsy, etc. method.Vital energy benefiting and the kidney invigorating is turbid with expectorant, and the kind high and level tone of easing the affected liver trembles surely.Seminar of the present invention " Chinese medicine composition " the auxiliary treatment PD motor complication of utilization in 2009 according to " secret recipe shakes ball surely " " bright Wang Kentang diagnosis and treatment criterion " change sanction has apparent in view advantage.Chinese medicine composition benefiting QI and nourishing blood, the endogenous wind stopping that reduces phlegm, QI and blood fill then wind-phlegm to be ended, irritability dredge then tremble flat.
The dosage Chinese medicine composition can suppress the carrying out property rising of actinal surface portion, upper limb AIM scoring during the present invention discovered, and long-term observation is heavy dose of and middle dosage does not have difference.And with regard to axially marking with rotation AIM, the middle dose groups of effect that the heavy dose of Chinese medicine composition of long-term observation suppresses the rising of carrying out property of AIM scoring is more effective.The dosage Chinese medicine composition can obviously reduce the generation of PD rat motor complication in the explanation, and heavy dose of Chinese medicine composition to axially with the more remarkable treatment effect of rotation symptom and stable.The medication to 2 of small dose group Chinese medicine composition is suppressed the carrying out property rising that AIM marks during week, brought into play preventive effect.Middle dosage Chinese medicine composition can reduce the AIM that Dopar produces in early days, and long-term observation is heavy dose of and middle dosage does not have difference.The dosage Chinese medicine composition is remarkable and stable to the AIM effect that reduces the levodopa generation in the explanation.Each item rating situation of change of comprehensive observing, the present invention finds that the medication to 2 of small dose group Chinese medicine composition has suppressed the carrying out property rising of AIM total points during week, brought into play preventive effect.Middle dosage Chinese medicine composition can reduce the AIM that Dopar produces in early days, and long-term observation is heavy dose of and middle dosage does not have difference.The dosage Chinese medicine composition is remarkable and stable to the AIM effect that reduces the levodopa generation in the explanation.In addition, middle dosage Chinese medicine composition can reduce the agent peak number of revolutions that Dopar produces, and dosage more has effect in the heavy dose of ratio of long-term observation.In a word, the present invention finds the have preventive effect of Chinese medicine composition for the PD motor complication.
Most scholars think that along with PD course of disease progress, compensation constantly appears in Basal ganglia DA, and the early stage Basal ganglia DA receptor of PD patient occurs ultra quick, and the receptor number increases (rise effect).The DA receptor belongs to GPCRs family, when DA receptor long term exposure in agonist, the agonist of same level can not make the effector of receptor activate, and after promptly agonist has activated GPCRs, also start a degenerative process, the mistake that is called receptor is quick.This process makes the film signal weakening, the potential injury of having avoided undue irritation cell to cause.Result of study of the present invention shows that the GRK6 expression reduces than sham operated rats during PD, and prompting DA receptor is ultra quick closely related with reduction GRK6.In addition, Western medicine group GRK6 expression further reduces than the PD group.This possibly be that GRK6 reduces along with the life-time service of levodopa, can't suppress the activation of ultra quick receptor abnormality signal, finally causes the generation of LID.What is more important, middle dosage Chinese medicine composition can suppress the reduction that GRK6 expresses, and have suppressed the ultra quick effect of DA receptor, have stoped the transmission of abnormal signal, thereby play the effect that the prevention motor complication takes place, and dosage increases more significantly preventive effect of not appearance.Equally, β during PD-arrestin1 protein expression reduces than sham operated rats, possibly be because the PD dopaminergic neuron is lost and degeneration in a large number, and residual dopamine neuron performance compensation increases the DA receptor sensitivity.And the Western medicine group β of life-time service levodopa treatment-arrestin1 expression further reduces than the PD group, and transduction suppressed to weaken β-arrestin1 to abnormal signal when this possibly be PD, thereby had caused the abnormal signal activation, had caused LID.Add rat with Chinese medicine composition; Small dose group can be prevented the further reduction of β-arrestin1 protein expression; And middle dose groups Chinese medicine composition not only suppresses the further reduction of β-arrestin1 protein expression; This value is increased, and the effect that prevention unusual fluctuation disease is taken place is more remarkable, and dosage increases more significantly preventive effect of not appearance.The dose groups Chinese medicine composition can increase β-arrestin1 protein expression in the explanation, plays the effect that prevention LID takes place.
Phosphorylated protein-32 (the dopamine and cAMP-regulated phosphoprotein of Mr 32000 that dopamine and adenosine cyclophosphate (cAMP) are regulated; DARPP-32) be expressed in the striatum projection neuron, in the signal conduction of dopamine, play an important role.PKA can promote the phosphorylation in the Thr34 site of DARPP-32; Simultaneously possibly pass through activator protein phosphatase-2A (PP-2A), make Thr75 site dephosphorylation.After the Thr34 site phosphorylation of DARPP-32, change the highly efficient depressor of protein phosphatase 1 (PP-1) into, thereby the phosphorylation state of modulin further influences the downstream signal conduction.Become the inhibitor of PKA after the Thr75 site phosphorylation of DARPP-32, the reduction of its phosphorylation degree has alleviated the inhibitory action to PKA.The difference that this shows phosphorylation site can be given DARPP-32 with opposite physiological effect.Seminar of the present invention early-stage Study finds that the phosphorylation of LID model striatum district ERK strengthens, and DARPP-32Thr75 site phosphorylation reduces, and the ERK and the DARPP-32 Mediated Signal Transduction of prompting PKA signal path strengthen.Extracellular signal-regulated kinase (Extracellular signal-regulated kinases; ERK) be the activated protein kinase of mitogen (Mitogen activated protein kinase; MAPK) member in the family is considered to the important modulation point from cell surface to nuclear signal transduction.ERK through the kinases MEK of MAPK on Thr202 and Tyr204 site phosphorylation modification (claim ERK1/2 again, P44/P42), after can participate in the adjusting of intracellular signal transduction widely.The medicine of prevention motor complication is (like adenosine A
2AReceptor antagonist, cannabinoid CB 1 receptor agonist) can weaken the unusual phosphorylation of ERK and DARPP-32; Prompting ERK and DARPP-32 have participated in the generation of motor complication; The enhancing of its function can activate the transcription factor in downstream; Influence the gene expression of striatum district, some important proteic phosphorylation levels that also adjustable participation striatum function is regulated.My seminar is observed the variation of total DARPP-32 of rat striatum Qu (Thr75) and phosphorylation DARPP-32 (Thr75) protein expression, finds that respectively organizing the total DARPP-32 of striatum Qu (Thr75) expression does not change.After the levodopa long-term treatment, phosphorylation DARPP-32 (Thr75) expression ratio PD group obviously reduces, add with in the dosage Chinese medicine composition can reverse the reduction of phosphorylation DARPP-32 (Thr75) expression.The DA receptor sensitivity increased when reason possibly be LID; The PKA path activates; Thereby reduced the Expression of phosphorylated in DARPP-32 albumen Thr75 site; The expression of phosphorylation DARPP-32 (Thr75) has been raised in the use of Chinese medicine composition, and the PKA path is suppressed to increase, and has reduced unusual motor behavior.Simultaneously, this research finds that through the variation of SABC and Western blot technology observation PD total ERK1/2 of rat striatum Qu and phosphorylation ERK1/2 protein expression respectively organizing total ERK protein expression does not have significant change.With regard to phosphorylation ERK1/2 albumen, the proteic expression of PD group phosphorylation ERK1/2 reduces than the sham operated rats rat, and phosphorylation ERK1/2 expresses significantly and raises after the levodopa long-term treatment, has the activation of ERK path during prompting LID.After the Chinese medicine auxiliary treatment, middle dose groups does not all occur significantly rising with heavy dose of group expression, and the dosage Chinese medicine composition has suppressed the abnormal activation of ERK path in showing, has played the effect of prevention LID.
In a word; Middle dosage Chinese medicine composition has reversed the carrying out property rising of each component AIM scoring of PD rat, has reduced PD rat agent peak number of revolutions, through increasing GRK6, β-arrestin1 expressing quantity; The reduction and the phosphorylation ERK1/2 that reverse phosphorylation DARPP-32 (Thr75) expression express significantly rising; Improved the function of anomalous signals transduction molecule in the LID born of the same parents, reduced the generation of PD motor complication, prevented PD and delaying to have great using value aspect the disease progression.
Three, conclusion
Chinese medicine composition of the present invention can reduce unusual involuntary movement scoring and the rat agent peak number of revolutions of unusual fluctuation disease rat; Reduced unusual fluctuation disease rat striatum phosphorylation ERK1/2 expression; Reverse the further decline that phosphorylation DARPP-32 (THr75) expresses; Reverse the reduction of GRK6 and β-arrestin1 expression, played the effect of prevention unusual fluctuation disease, can be used as effective ancillary drug of PD motor complication prevention.
Chinese medicine composition of the present invention, its compatibility meet Chinese medicine " monarch " principle, and the flavour of a drug number is less; Advantages such as having the curative effect height, have no side effect, price is low adopts the benefiting QI for activating blood circulation method, the nourishing YIN for attracting YANG method; The suppressing the hyperactive liver to relieve the wind syndrome method is rubbed the muscle method that relieves dizziness, high fever, infantile convulsions, epilepsy, etc., activating blood and removing stasis Method and collateral dredging rule such as relieve dizziness, high fever, infantile convulsions, epilepsy, etc.; Start with from cause of disease at all, suit the remedy to the case, to reach preventive effect; Method for preparing is simple, and cost is low, and is environmentally friendly, is suitable for taking for a long time, is a kind of Chinese medicine composition that prevents parkinson disease and parkinson disease motor complication safely and effectively, has a good application prospect.
The above only is a preferred implementation of the present invention; Should be pointed out that for those skilled in the art, under the prerequisite that does not break away from the inventive method; Can also make some improvement and replenish, these improvement and replenish and also should be regarded as protection scope of the present invention.
Claims (9)
1. the application of Chinese medicine composition in the Parkinsonian disease medicament of preparation prevention; It is characterized in that described Chinese medicine composition is processed by following bulk drugs: Rhizoma Gastrodiae 5-12 part, Radix Astragali 5-10 part, Radix Rehmanniae Preparata 5-10 part, Radix Paeoniae Alba 5-15 part, Radix Angelicae Sinensis 5-10 part, Ramulus Uncariae Cum Uncis 5-10 part, Bombyx Batryticatus 2-10 part.
2. application according to claim 1; It is characterized in that described Chinese medicine composition is processed by following bulk drugs: Rhizoma Gastrodiae 6-10 part, Radix Astragali 6-9 part, Radix Rehmanniae Preparata 6-9 part, Radix Paeoniae Alba 8-13 part, Radix Angelicae Sinensis 6-7 part, Ramulus Uncariae Cum Uncis 6-9 part, Bombyx Batryticatus 4-6 part.
3. application according to claim 1 is characterized in that, described Chinese medicine composition is processed by following bulk drugs: 8 parts in Rhizoma Gastrodiae, 8 parts of the Radixs Astragali, 8 parts of Radix Rehmanniae Preparata, 10 parts of Radix Paeoniae Alba, 7 parts of Radix Angelicae Sinensis, 8 parts of Ramulus Uncariae Cum Uncis, 6 parts of Bombyx Batryticatus.
4. according to the arbitrary described application of claim 1-3, it is characterized in that the application of described Chinese medicine composition in the disease medicament of preparation prevention parkinson disease motor complication.
5. one kind is prevented Parkinsonian Chinese medicine composition; It is characterized in that described Chinese medicine composition is processed by following bulk drugs: Rhizoma Gastrodiae 5-12 part, Radix Astragali 5-10 part, Radix Rehmanniae Preparata 5-10 part, Radix Paeoniae Alba 5-15 part, Radix Angelicae Sinensis 5-10 part, Ramulus Uncariae Cum Uncis 5-10 part, Bombyx Batryticatus 2-10 part.
6. Chinese medicine composition according to claim 1; It is characterized in that described Chinese medicine composition is processed by following bulk drugs: Rhizoma Gastrodiae 6-10 part, Radix Astragali 6-9 part, Radix Rehmanniae Preparata 6-9 part, Radix Paeoniae Alba 8-13 part, Radix Angelicae Sinensis 6-7 part, Ramulus Uncariae Cum Uncis 6-9 part, Bombyx Batryticatus 4-6 part.
7. Chinese medicine composition according to claim 1 is characterized in that, described Chinese medicine composition is processed by following bulk drugs: 8 parts in Rhizoma Gastrodiae, 8 parts of the Radixs Astragali, 8 parts of Radix Rehmanniae Preparata, 10 parts of Radix Paeoniae Alba, 7 parts of Radix Angelicae Sinensis, 8 parts of Ramulus Uncariae Cum Uncis, 6 parts of Bombyx Batryticatus.
8. according to the arbitrary described Chinese medicine composition of claim 5-7, it is characterized in that the application of described Chinese medicine composition in the disease medicament of preparation prevention parkinson disease motor complication.
9. according to the arbitrary described Chinese medicine composition of claim 5-7, it is characterized in that the dosage form of described Chinese medicine composition is tablet, capsule, granule, mixture, oral liquid or syrup.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210063008.3A CN102600372B (en) | 2012-03-12 | 2012-03-12 | Chinese medicinal composition for preventing Parkinsonism |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210063008.3A CN102600372B (en) | 2012-03-12 | 2012-03-12 | Chinese medicinal composition for preventing Parkinsonism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102600372A true CN102600372A (en) | 2012-07-25 |
| CN102600372B CN102600372B (en) | 2014-01-22 |
Family
ID=46518391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210063008.3A Expired - Fee Related CN102600372B (en) | 2012-03-12 | 2012-03-12 | Chinese medicinal composition for preventing Parkinsonism |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102600372B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104800604A (en) * | 2015-04-20 | 2015-07-29 | 韩萍 | Traditional Chinese medicine formula for treating Parkinsonism |
| CN109432306A (en) * | 2018-12-20 | 2019-03-08 | 上海交通大学医学院附属新华医院 | Pharmaceutical composition and its application |
| CN115429863A (en) * | 2022-09-01 | 2022-12-06 | 河南大学第一附属医院 | Traditional Chinese medicine composition for treating non-motor symptoms related to Parkinson's disease |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101269188A (en) * | 2008-05-15 | 2008-09-24 | 天科仁祥技术（北京）有限责任公司 | Traditional Chinese medicine combination for treating parkinsonism and preparation method thereof |
-
2012
- 2012-03-12 CN CN201210063008.3A patent/CN102600372B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101269188A (en) * | 2008-05-15 | 2008-09-24 | 天科仁祥技术（北京）有限责任公司 | Traditional Chinese medicine combination for treating parkinsonism and preparation method thereof |
Non-Patent Citations (5)
| Title |
|---|
| 严兴亚等: "帕金森病中医药治疗研究进展", 《现代中西医结合杂志》, vol. 17, no. 15, 31 May 2008 (2008-05-31), pages 2407 - 2409 * |
| 周小琳: "镇颤舒胶囊合美多巴治疗帕金森病42例临床研究", 《山西中医》, vol. 20, no. 1, 29 February 2004 (2004-02-29), pages 23 - 24 * |
| 张秋娟等: "中医药治疗帕金森病的思路与方法", 《中西医结合学报》, vol. 2, no. 1, 31 January 2004 (2004-01-31), pages 75 - 77 * |
| 徐瑰翎: "天麻对帕金森病大鼠神经元保护及机制的研究", 《中国优秀硕士学位论文全文数据库》, no. 2, 15 February 2008 (2008-02-15), pages 78 * |
| 王洁等: "中西药合用对异动症大鼠行为学和氧化应激的影响", 《河北中医》, vol. 31, no. 1, 31 January 2009 (2009-01-31), pages 123 - 124 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104800604A (en) * | 2015-04-20 | 2015-07-29 | 韩萍 | Traditional Chinese medicine formula for treating Parkinsonism |
| CN109432306A (en) * | 2018-12-20 | 2019-03-08 | 上海交通大学医学院附属新华医院 | Pharmaceutical composition and its application |
| CN115429863A (en) * | 2022-09-01 | 2022-12-06 | 河南大学第一附属医院 | Traditional Chinese medicine composition for treating non-motor symptoms related to Parkinson's disease |
| CN115429863B (en) * | 2022-09-01 | 2023-10-13 | 河南大学第一附属医院 | Traditional Chinese medicine composition for treating parkinsonism-related non-motor symptoms |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102600372B (en) | 2014-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103110744B (en) | Traditional Chinese medical health-care preparation for increasing bone density and preparation method thereof | |
| CN101062080B (en) | Medicinal composition for relieving fatigue and preparing process thereof | |
| CN103721102A (en) | Chinese patent medicine for treating vascular dementia and preparation method thereof | |
| CN102600370B (en) | Application of Chinese medicinal composition in preparing medicament for preventing and treating Parkinsonism | |
| CN102600372B (en) | Chinese medicinal composition for preventing Parkinsonism | |
| CN101317964B (en) | Chinese medicinal composition with spleen-enlivening and kidney-tonifying function, preparation and uses thereof | |
| CN102600373B (en) | Traditional Chinese medicine composition for relieving parkinsonism motion complications | |
| CN111407853B (en) | Traditional Chinese medicine composition for treating Parkinson's disease and preparation method thereof | |
| CN102526512A (en) | Medicine for treating motor complications of Parkinson's diseases and application thereof | |
| CN109700973B (en) | Traditional Chinese medicine composition for promoting regeneration of hippocampal neuronal cells | |
| CN101357184A (en) | Chinese traditional medicine for treating hepatosis and preparation method thereof | |
| CN102600371B (en) | Traditional Chinese medicine composition for preventing parkinsonism and application of traditional Chinese medicine composition | |
| CN103330837B (en) | Traditional Chinese medicine composition for curing osteoporosis of menopausal women | |
| CN102600374B (en) | Medicine for preventing parkinsonism and application of medicine | |
| CN102600375B (en) | Medicine for treating parkinsonism motion complications and application of medicine | |
| CN102579847B (en) | Application of Chinese medicinal composition in preparing medicament for treating motion complications of Parkinson's disease | |
| CN103007204B (en) | Chinese medicinal composition for treating hepatofibrosis | |
| CN107582969B (en) | Compound preparation for treating autoimmune thyroid diseases and preparation method thereof | |
| CN107648397B (en) | Traditional Chinese medicine composition for treating liver-kidney yin deficiency and preparation method and application thereof | |
| CN100534486C (en) | Chinese medicinal preparation for treating proteinuria caused by diabetic nephropathy and preparation method thereof | |
| CN103977154A (en) | Pharmaceutical composition for protecting liver | |
| CN110215508A (en) | A kind of preparation process of Shu Yu herbal mixture and its manufactured dosage form and each dosage form | |
| CN104208640A (en) | Traditional Chinese medicine composition for treating delayed menstrual cycle | |
| CN114306497B (en) | Traditional Chinese medicine composition for treating kidney deficiency and blood stasis type osteoporosis, preparation and application | |
| CN112791166B (en) | Medicinal and edible composition for enhancing muscle performance and relieving exercise-induced fatigue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140122 Termination date: 20150312 |
|
| EXPY | Termination of patent right or utility model |